XPS with Steen Solution Perfusate
Xvivo Perfusion, Inc. · Decision date Nov 25, 2025
What did the FDA approve?
FDA records P180014/S013 as a supplement to PMA P180014, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 25, 2025.
FDA approval order statement
Approval for material changes to the organ chamber elbow fitting and the lung cannula set luer connector
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Nov 25, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P180014/S013
- Regulatory pathway
- PMA supplement
- Applicant
- Xvivo Perfusion, Inc.
- Product code
- PHO
- Decision code
- APPR
- Decision date
- Nov 25, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Normothermic preservation system for transplantation of initially unacceptable donor lungs.
- Applicant
- Xvivo Perfusion, Inc.
- Product code
- PHO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P180014. Subsequent supplements may change the device or its indications.
FDA decision timeline
P180014 · Original PMA
XPS with Steen Solution Perfusate
P180014/S013 received
Application receipt date recorded by FDA.
P180014/S013 · FDA decision
Real-Time Process
P180014/S014 · Related supplement
XPS with Steen Solution Perfusate
Timeline entries are records held by MedtechLedger for P180014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Xvivo Perfusion, Inc. | PMA approval | Apr 26, 2019 | FDA | |
XPS with Steen Solution PerfusateP180014/S014 | Xvivo Perfusion, Inc. | PMA supplement | Sep 16, 2026 | FDA |
Explore the linked device profile
Other records with product code PHO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
LungFX DeviceP240033/S001 | Lung Bioengineering, Inc. | PMA supplement | Oct 16, 2026 | FDA |
LungFX DeviceP240033/S002 | Lung Bioengineering, Inc. | PMA supplement | Oct 16, 2026 | FDA |
TorEx Lung Perfusion SystemP250025 | Traferox Technologies, Inc. | PMA approval | Jul 15, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Xvivo Perfusion, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3666 S Inca St., Englewood, CO, 80110
Sources and methodology
- Original FDA record: P180014/S013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





